{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreie6yultvzfrmahmaf2hdcfgge7duqtewps5vta43wpnq2zsud5rvq",
    "uri": "at://did:plc:izotgtw5czjnuqtpcldjnkjh/app.bsky.feed.post/3mfy27mhsktc2"
  },
  "path": "/scientists-uncover-the-hidden-mechanism-behind-fda-approved-alzheimers-drug/",
  "publishedAt": "2026-02-28T16:57:21.000Z",
  "site": "https://scitechdaily.com",
  "tags": [
    "Health",
    "Alzheimer's Disease",
    "Brain",
    "Dementia",
    "Microglia",
    "Neurology",
    "Neuroscience"
  ],
  "textContent": "Scientists show that lecanemab clears amyloid plaques by engaging microglia through its Fc fragment, defining the cellular program behind its therapeutic effect Lecanemab, marketed as Leqembi, is a monoclonal antibody treatment for Alzheimer’s disease that reduces the buildup of toxic amyloid plaques in the brain and slows cognitive decline. Scientists from VIB and KU Leuven [...]",
  "title": "Scientists Uncover the Hidden Mechanism Behind FDA-Approved Alzheimer’s Drug"
}